FULCFulcrum Therapeutics, Inc.

After completion of the merger, the combined company will develop Slate’s migraine treatment pipeline.

By Karen Roman Fulcrum Therapeutics, Inc. (Nasdaq: FULC) said it is merging with Slate Medicines, Inc. to advance next-generation therapeutics to treat migraine and other headache disorders, with the combining company operating as Slate Medicines, Inc. and trading on Nasdaq under the ticker “SLTE.” Slate reported it secured an oversubscribed concurrent private placement of $245 […] The post Fulcrum Therapeutics & Slate Medicines Merge for Next-Generation Migraine Therapies appeared first on Exec

Fulcrum Therapeutics (NASDAQ:FULC) has entered into an all-stock merger agreement with privately held Slate Medicines, a migraine-focused biotechnology company, in a transaction expected to close in the fourth quarter of 2026, subject to stockholder approval and customary closing conditions. Alex S

Fulcrum Therapeutics (FULC) and Slate Medicines said Monday they have agreed to combine in an all-st

Fulcrum announced in June it would seek strategic alternatives after U.S. regulators expressed concern over the viability of its sickle cell drug.

The updated analyst framework for Fulcrum Therapeutics lifts the Fair Value estimate from US$5.43 to US$5.83 per share. This shift in price target sits against a backdrop of sharply changed Street commentary after the decision to discontinue pociredir, with more focus on cash, restructuring and the ongoing review of options than on late stage development potential. Read on to see how this evolving narrative could matter for your own view on Fulcrum Therapeutics and how to track the next set...